Serum brain-derived neurotrophic factor and the risk for dementia: The framingham heart study

JAMA Neurology

Volumn 71, Issue 1, 2014, Pages 55-61

  Weinstein, Galit ^a,b   Beiser, Alexa S ^a,b,c   Choi, Seung Hoan ^c   Preis, Sarah R ^a   Chen, Tai C ^a   Vorgas, Demetrios ^a   Au, Rhoda ^a,b   Pikula, Aleksandra ^a,b   Wolf, Philip A ^a,b   DeStefano, Anita L ^a,b,c   Vasan, Ramachandran S ^a,b   Seshadri, Sudha ^a,b  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b FRAMINGHAM HEART STUDY   (United States)

^c BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR;

AGED; ALZHEIMER DISEASE; BLOOD; DEMENTIA; FEMALE; GENETICS; GENOTYPE; HUMAN; INCIDENCE; MALE; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; RISK; SENSITIVITY AND SPECIFICITY; SINGLE NUCLEOTIDE POLYMORPHISM; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; BRAIN-DERIVED NEUROTROPHIC FACTOR; DEMENTIA; FEMALE; GENOTYPE; HUMANS; INCIDENCE; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK; SENSITIVITY AND SPECIFICITY;

EID: 84892430869     PISSN: 21686149     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaneurol.2013.4781     Document Type: Article

References (51)

1. Seshadri S, Wolf PA Lifetime risk of stroke and dementia: current concepts, and estimates from the Framingham Study. Lancet Neurol. 2007; 6(12):1106-1114.
2. Ferri CP, Prince M, Brayne C., et al.; Alzheimer's Disease International. Global prevalence of dementia: a Delphi Consensus Study. Lancet. 2005; 366(9503):2112-2117.
3. Lee J, Seroogy KB, Mattson MP Dietary restriction enhances neurotrophin expression and neurogenesis in the hippocampus of adult mice. J Neurochem. 2002; 80(3):539-547.
4. Neeper SA, Gómez-Pinilla F, Choi J, Cotman C. Exercise and brain neurotrophins. Nature. 1995; 373(6510):109.
5. Vaynman S, Ying Z, Gomez-Pinilla F. Interplay between brain-derived neurotrophic factor and signal transduction modulators in the regulation of the effects of exercise on synaptic-plasticity. Neuroscience. 2003; 122(3):647-657.
6. Phillips HS, Hains JM, Laramee G.R., Rosenthal A., Winslow JW Widespread expression of BDNF but not NT3 by target areas of basal forebrain cholinergic neurons. Science. 1990; 250(4978): 290-294.
7. Wetmore C, Ernfors P, Persson H., Olson L. Localization of brain-derived neurotrophic factor mRNA to neurons in the brain by in situ hybridization. Exp Neurol. 1990; 109(2):141-152.
8. Ghosh A, Carnahan J, Greenberg ME Requirement for BDNF in activity-dependent survival of cortical neurons. Science. 1994; 263(5153):1618-1623.
9. Lindholm D, Carroll P, Tzimagiogis G., Thoenen H. Autocrine-paracrine regulation of hippocampal neuron survival by IGF-1 and the neurotrophins BDNF, NT-3 and NT-4. Eur J Neurosci. 1996; 8(7):1452-1460.
10. Alderson RF, Alterman AL, Barde Y.A., Lindsay RM Brain-derived neurotrophic factor increases survival and differentiated functions of rat septal cholinergic neurons in culture. Neuron. 1990; 5(3):297-306.
11. Hyman C, Hofer M, Barde Y.A., et al BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra. Nature. 1991; 350(6315): 230-232.
12. Alonso M, Vianna MR, Depino A.M., et al BDNF-triggered events in the rat hippocampus are required for both short- and long-term memory formation. Hippocampus. 2002; 12(4):551-560.
13. Bekinschtein P, Cammarota M, Izquierdo I., Medina JH BDNF and memory formation and storage. Neuroscientist. 2008; 14(2):147-156.
14. Erickson KI, Prakash RS, Voss M.W., et al Brain-derived neurotrophic factor is associated with age-related decline in hippocampal volume. J Neurosci. 2010; 30(15):5368-5375.
15. Komulainen P, Pedersen M, Hänninen T, et al BDNF is a novel marker of cognitive function in ageing women: the DR's EXTRA Study. Neurobiol Learn Mem. 2008; 90(4):596-603.
16. Peng S, Wuu J, Mufson E.J., Fahnestock M. Precursor form of brain-derived neurotrophic factor and mature brain-derived neurotrophic factor are decreased in the pre-clinical stages of Alzheimer's disease. J Neurochem. 2005; 93(6):1412-1421.
17. Durany N, Michel T, Kurt J., Cruz-Sanchez FF, Cervas-Navarro J, Riederer P. Brain-derived neurotrophic factor and neurotrophin-3 levels in Alzheimer's disease brains. Int J Dev Neurosci. 2000; 18(8):807-813.
18. Lee JG, Shin BS, You Y.S., et al Decreased serum brain-derived neurotrophic factor levels in elderly korean with dementia. Psychiatry Investig. 2009; 6(4):299-305.
19. Laske C, Stransky E, Leyhe T., et al BDNF serum and CSF concentrations in Alzheimer's disease, normal pressure hydrocephalus and healthy controls. J Psychiatr Res. 2007; 41(5):387-394.
20. Forlenza OV, Diniz BS, Teixeira A.L., et al Effect of brain-derived neurotrophic factor Val66Met polymorphism and serum levels on the progression of mild cognitive impairment. World J Biol Psychiatry. 2010; 11(6):774-780.
21. Yasutake C, Kuroda K, Yanagawa T., Okamura T, Yoneda H. Serum BDNF, TNF-alpha and IL-1beta levels in dementia patients: comparison between Alzheimer's disease and vascular dementia. Eur Arch Psychiatry Clin Neurosci. 2006; 256(7): 402-406.
22. O'Bryant S.E., Hobson VL, Hall J.R., et al.; Texas Alzheimer's Research Consortium. Serum brain-derived neurotrophic factor levels are specifically associated with memory performance among Alzheimer's disease cases. Dement Geriatr Cogn Disord. 2011; 31(1):31-36.
23. Bus BA, Molendijk ML, Penninx B.J., et al Determinants of serum brain-derived neurotrophic factor. Psychoneuroendocrinology. 2011; 36(2):228-239.
24. Bus BA, Tendolkar I, Franke B., et al Serum brain-derived neurotrophic factor: determinants and relationship with depressive symptoms in a community population of middle-aged and elderly people. World J Biol Psychiatry. 2012; 13(1):39-47.
25. Richards M, Sacker A. Lifetime antecedents of cognitive reserve. J Clin Exp Neuropsychol. 2003; 25(5):614-624.
26. Andel R, Vigen C, Mack W.J., Clark LJ, Gatz M. The effect of education and occupational complexity on rate of cognitive decline in Alzheimer's patients. J Int Neuropsychol Soc. 2006; 12(1):147-152.
27. Qiu C, Kivipelto M, von Strauss E. Epidemiology of Alzheimer's disease: occurrence, determinants, and strategies toward intervention. Dialogues Clin Neurosci. 2009; 11(2):111-128.
28. Dawber TR, Meadors GF, Moore FE Jr. Epidemiological approaches to heart disease: the Framingham Study. Am J Public Health Nations Health. 1951; 41(3):279-281.
29. Feinleib M, Kannel WB, Garrison R.J., McNamara PM, Castelli WP The Framingham Offspring Study: design and preliminary data. Prev Med. 1975; 4(4):518-525.
30. Seshadri S, Wolf PA, Beiser A, et al Lifetime risk of dementia and Alzheimer's disease: the impact of mortality on risk estimates in the Framingham Study. Neurology. 1997; 49(6):1498-1504.
31. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.
32. McKhann G, Drachman D, Folstein M., Katzman R, Price D, Stadlan EM Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984; 34(7): 939-944.
33. Berg L. Clinical Dementia Rating (CDR). Psychopharmacol Bull. 1988; 24(4):637-639.
34. Wolf PA, D'Agostino RB, Belanger AJ, Kannel WB Probability of stroke: a risk profile from the Framingham Study. Stroke. 1991; 22(3):312-318.
35. Seshadri S, Wolf PA, Beiser A.S., et al Association of plasma total homocysteine levels with subclinical brain injury: cerebral volumes, white matter hyperintensity, and silent brain infarcts at volumetric magnetic resonance imaging in the Framingham Offspring Study. Arch Neurol. 2008; 65(5):642-649.
36. Beekman AT, Deeg DJ, Van Limbeek J, Braam AW, De Vries MZ, Van Tilburg W. Criterion validity of the Center for Epidemiologic Studies Depression scale (CES-D): results from a community-based sample of older subjects in the Netherlands. Psychol Med. 1997; 27(1):231-235.
37. Kannel WB, Sorlie P. Some health benefits of physical activity: the Framingham Study. Arch Intern Med. 1979; 139(8):857-861.
38. Seshadri S, Fitzpatrick AL, Ikram M.A., et al.; CHARGE Consortium; GERAD1 Consortium; EADI1 Consortium. Genome-wide analysis of genetic loci associated with Alzheimer disease. JAMA. 2010; 303(18):1832-1840.
39. Bäckman L., Jones S, Berger A.K., Laukka EJ, Small BJ Multiple cognitive deficits during the transition to Alzheimer's disease. J Intern Med. 2004; 256(3):195-204.
40. Elias MF, Beiser A, Wolf P.A., Au R., White RF, D'Agostino RB. The preclinical phase of Alzheimer disease: a 22-year prospective study of the Framingham Cohort. Arch Neurol. 2000; 57(6):808-813.
41. Debette S, Beiser A, DeCarli C., et al Association of MRI markers of vascular brain injury with incident stroke, mild cognitive impairment, dementia, and mortality: the Framingham Offspring Study. Stroke. 2010; 41(4):600-606.
42. Tondelli M, Wilcock GK, Nichelli P, De Jager CA, Jenkinson M, Zamboni G. Structural MRI changes detectable up to ten years before clinical Alzheimer's disease. Neurobiol Aging. 2012; 33(4):825.e825-836.
43. Kaye JA, Swihart T, Howieson D., et al Volume loss of the hippocampus and temporal lobe in healthy elderly persons destined to develop dementia. Neurology. 1997; 48(5):1297-1304.
44. Whitmer RA, Sidney S, Selby J., Johnston SC, Yaffe K. Midlife cardiovascular risk factors and risk of dementia in late life. Neurology. 2005; 64(2):277-281.
45. Kivipelto M, Helkala EL, Laakso M.P., et al Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study. BMJ. 2001; 322(7300):1447-1451.
46. Sperling RA, Aisen PS, Beckett L.A., et al Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011; 7(3):280-292.
47. Fukumoto N, Fujii T, Combarros O., et al Sexually dimorphic effect of the Val66Met polymorphism of BDNF on susceptibility to Alzheimer's disease: new data and meta-analysis. Am J Med Genet B Neuropsychiatr Genet. 2010; 153B(1):235-242.
48. Scharfman HE, MacLusky NJ Estrogen and brain-derived neurotrophic factor (BDNF) in hippocampus: complexity of steroid hormone-growth factor interactions in the adult CNS. Front Neuroendocrinol. 2006; 27(4):415-435.
49. Kaur P, Jodhka PK, Underwood W.A., et al Progesterone increases brain-derived neurotrophic factor expression and protects against glutamate toxicity in a mitogen-activated protein kinase- and phosphoinositide-3 kinase-dependent manner in cerebral cortical explants. J Neurosci Res. 2007; 85(11):2441-2449.
50. Tapia-Arancibia L., Aliaga E, Silhol M., Arancibia S. New insights into brain BDNF function in normal aging and Alzheimer disease. Brain Res Rev. 2008; 59(1):201-220.
51. Lee ST, Chu K, Jung K.H., et al miR-206 regulates brain-derived neurotrophic factor in Alzheimer disease model. Ann Neurol. 2012; 72(2):269-277.